Johnson & Johnson is trading at $274.87, up +3.27% versus the November 3 close, in line with a broader pre-market rally after Democrats gained control of both congressional chambers. - Healthcare stocks also advanced. - The company’s positive Shockwave Javelin study results were announced November 1, so they are not a clear new overnight catalyst. - Smith+Nephew confirmed November 4 that merger discussions involving Johnson & Johnson’s orthopedics business had ended; available reporting does not establish that this drove the move.